Concord Biotech jumps on USFDA nod for transplant drug
Concord Biotech shares extended gains this week after the company received US Food and Drug Administration approval for its mycophenolate mofetil oral suspension, tapping an estimated $30 million US immunosuppressant market. The stock rallied despite a weak March quarter, with investors betting the new product will support the company’s US and international growth plans.
Market overview: Concord Biotech price jump
| Metric | Detail |
|---|---|
| Latest intraday move (Wednesday) | Shares up as much as 8.46%, intraday high at ₹1,264.90 |
| Previous session close (Tuesday) | Ended 11.18% higher at ₹1,180 |
| Earlier close (BSE reference)** | ₹1,166.80, up ₹106.20 or 10.01% on June 2 |
| 52-week high | ₹2,150 |
| 52-week low | ₹987 |
| Market capitalisation | Approx. ₹12,200 crore |
| Year-to-date performance | Stock down about 12% in 2026 despite recent rally |
- Concord Biotech shares reacted to the USFDA approval for a key transplant drug.
- The price jump followed two consecutive strong sessions on June 2 and June 3.
- Despite the rebound, the stock trades well below its 52-week high of ₹2,150.
USFDA approval and product details
| Aspect | Detail |
|---|---|
| Regulator | U.S. Food and Drug Administration (USFDA) |
| Approval type | Abbreviated New Drug Application (ANDA) |
| Product | Mycophenolate mofetil for oral suspension USP, 200 mg/mL |
| Therapeutic class | Antimetabolite immunosuppressant |
| Indication | Prophylaxis of organ rejection in kidney, heart, liver transplants |
| Patient group | Adult and paediatric patients 3 months and older |
| Use | In combination with other immunosuppressive therapies |
| Estimated US market size | Approx. $30 million |
- The company said the approval aligns with its long-term growth strategy.
- Concord expects the product to strengthen its US portfolio and transplant franchise.
- The company plans to leverage the approval to expand across US and other regulated markets.
- There were no withdrawal, cancellation, or suspension actions tied to the approval.
Financial performance and dividend
| Metric (Q4) | Current | Year-ago | Change |
|---|---|---|---|
| Net profit | ₹88.8 crore | ₹140.4 crore | -36.8% |
| Revenue from operations | ₹326.1 crore | ₹429.9 crore | -24.1% |
| EBITDA | ₹118.5 crore | ₹190.4 crore* | -37.8% |
| EBITDA margin | 36.4% | 44.3% | Margin contraction |
*EBITDA base derived from stated percentage decline.
- The company cited lower revenue and margin contraction for the profit decline.
- Concord Biotech remains positioned as an R&D-driven biopharmaceutical player.
- Board recommended a dividend of ₹7.55 per share (face value ₹1) for FY26.
- Record date for dividend eligibility is 24 July 2026, subject to shareholder approval.
Technical and valuation snapshot
| Indicator | Value | Context |
|---|---|---|
| Relative Strength Index (RSI-14) | 56.2 | Indicates neutral to positive momentum |
| Simple moving averages | Above 6 of 8 key SMAs | Suggests broadly positive trend setup |
| Price-to-earnings (P/E) | 42.56 | Reflects premium valuation for growth profile |
| Price-to-book (P/B) | 6.13 | Indicates rich pricing versus book value |
- The stock’s RSI level stays below the typical overbought threshold of 70.
- Trading above most key SMAs signals improving technical structure after recent gains.
Shareholding trends
| Investor class | March 2026 stake | Previous quarter | Trend |
|---|---|---|---|
| Foreign institutional investors (FIIs) | 7.79% | 7.58% | Marginal increase |
| Mutual funds | 4.30% | 4.44% | Slight reduction |
- FII buying indicates sustained institutional interest despite earnings pressure.
- Mutual funds trimmed exposure modestly in the March quarter.
Strategic outlook
- Concord said the USFDA nod will enhance its product offerings in the US market.
- The company expects the approval to support long-term growth across international markets.
- Industry estimates of a $30 million US market provide a defined commercial opportunity.
- The transplant-focused drug fits the company’s strategy in complex, regulated therapies.
FAQs
Why did the Concord Biotech share price jump this week?
The stock rose after USFDA approved Concord Biotech’s mycophenolate mofetil oral suspension, opening access to an estimated $30 million US immunosuppressant market.
What is mycophenolate mofetil used for?
It is an antimetabolite immunosuppressant used with other drugs to prevent organ rejection in adult and paediatric kidney, heart, and liver transplant patients aged three months and above.
How is Concord Biotech performing financially despite the approval?
In the latest reported quarter, net profit fell 36.8% year-on-year to ₹88.8 crore, with revenue down 24.1%, though the company has proposed a ₹7.55 per share dividend for FY26.
Why did the Concord Biotech share price jump this week?
The stock rallied after USFDA approved Concord Biotech’s mycophenolate mofetil oral suspension, giving it access to an estimated $30 million US immunosuppressant market and strengthening its US transplant portfolio.
What is mycophenolate mofetil used for?
Mycophenolate mofetil is an antimetabolite immunosuppressant used with other therapies to prevent organ rejection in adult and paediatric kidney, heart, and liver transplant patients aged three months and older.
How did Concord Biotech perform in the latest quarter?
For the latest reported quarter, Concord Biotech’s net profit declined 36.8% year-on-year to ₹88.8 crore, revenue fell 24.1% to ₹326.1 crore, EBITDA dropped 37.8%, and the board recommended a ₹7.55 per share dividend for FY26.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
